Eye Test Reportedly “Sees” Alzheimer’s Disease

Cognoptix’s Sapphire II eye test identified Alzheimer’s disease patients via a beta amyloid (“Ab”) signature in their eyes in a 10-subject proof-of-concept clinical trial, according to a company spokesperson. By detecting a specific fluorescent signature of ligand-marked beta amyloid in the supranucleus region of the human lens, the eye test achieved a 200% differentiation factor between a group of five healthy volunteers and a group of five patients diagnosed with probable Alzheimer’s. The clinical data are published (“Alzheimer’s disease diagnosis by detecting exogenous fluorescent signal of ligand bound to beta amyloid in the lens of human eye: an exploratory study”) in the May 2013 edition of Frontiers in Neurology. In addition, the data are being presented in a poster session at the Alzheimer’s Association International Conference (AAIC) in Boston in July. Read more.